



## Clinical trial results:

### A Randomised, Multicentre, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream Compared to Vehicle and Active Comparator in Subjects with Mild-to-Moderate Psoriasis Vulgaris

#### Summary

|                          |                 |
|--------------------------|-----------------|
| EudraCT number           | 2018-001970-66  |
| Trial protocol           | CZ              |
| Global end of trial date | 02 October 2020 |

#### Results information

|                                |                  |
|--------------------------------|------------------|
| Result version number          | v1 (current)     |
| This version publication date  | 30 November 2020 |
| First version publication date | 30 November 2020 |

#### Trial information

##### Trial identification

|                       |           |
|-----------------------|-----------|
| Sponsor protocol code | MC2-01-C7 |
|-----------------------|-----------|

##### Additional study identifiers

|                                    |                    |
|------------------------------------|--------------------|
| ISRCTN number                      | -                  |
| ClinicalTrials.gov id (NCT number) | NCT03802344        |
| WHO universal trial number (UTN)   | -                  |
| Other trial identifiers            | IND number: 127152 |

Notes:

#### Sponsors

|                              |  |
|------------------------------|--|
| Sponsor organisation name    | MC2 Therapeutics Ltd   |
| Sponsor organisation address | C/O Agern Allé 24-26, Hørsholm, Denmark, 2970  |
| Public contact               | Senior Project Manager, Clinical Operations, MC2 Therapeutics Ltd, +45 20157033, isa@mc2Therapeutics.com |
| Scientific contact           | Senior Project Manager, Clinical Operations, MC2 Therapeutics Ltd, +45 20157033, isa@mc2Therapeutics.com |

Notes:

#### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |                 |
|--|-----------------|
| Analysis stage                                       | Final           |
| Date of interim/final analysis                       | 02 October 2020 |
| Is this the analysis of the primary completion data? | Yes             |
| Primary completion date                              | 02 October 2020 |
| Global end of trial reached?                         | Yes             |
| Global end of trial date                             | 02 October 2020 |
| Was the trial ended prematurely?                     | No              |

Notes:

## General information about the trial

Main objective of the trial:

The primary objective is to evaluate the efficacy of MC2-01 cream compared to active comparator in subjects with psoriasis vulgaris.

Protection of trial subjects:

The MC2-01 cream contains two well-known active compounds (CAL/BDP) in a novel topical formulation. The efficacy and safety profile of the combination is well established and have proven to be safe and efficacious, and available data for MC2-01 cream suggest a very benign safety profile resembling that known from the approved CAL/BDP products. A cream formulation of CAL and BDP may benefit subjects by providing improved convenience and ease of use resulting in increased patient adherence to therapy which will improve real-life treatment outcome.

Daivobet gel is used as comparator for this trial. The common AE (>1%) is pruritus. Other uncommon AEs are folliculitis, skin infections, exacerbation of psoriasis, dermatitis, erythema, rash, skin irritation, skin burning sensation, application site pain, as well as eye irritation (i.e.  $\geq 0.1\%$  and  $< 1\%$ ).

It was thus considered that the benefit of obtaining clinical data for this trial outweighed any potential risks.

AEs were collected/assessed from the time of the signature of the informed consent form by the subject and until the final follow-up visit. AEs that were considered related to the trial product would be followed until they were resolved, or until the medical condition of the subject was stable.

Background therapy: -

Evidence for comparator:

Daivobet gel was used as comparator product. It is a approved product with a well known safety profile.

|   |                  |
|---|------------------|
| Actual start date of recruitment                          | 12 December 2018 |
| Long term follow-up planned                               | No               |
| Independent data monitoring committee (IDMC) involvement? | No               |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                     |
|--------------------------------------|---------------------|
| Country: Number of subjects enrolled | Poland: 129         |
| Country: Number of subjects enrolled | Czech Republic: 147 |
| Country: Number of subjects enrolled | Germany: 214        |
| Worldwide total number of subjects   | 490                 |
| EEA total number of subjects         | 490                 |

Notes:

| <b>Subjects enrolled per age group</b>    |     |
|---|-----|
| In utero                                  | 0   |
| Preterm newborn - gestational age < 37 wk | 0   |
| Newborns (0-27 days)                      | 0   |
| Infants and toddlers (28 days-23 months)  | 0   |
| Children (2-11 years)                     | 0   |
| Adolescents (12-17 years)                 | 0   |
| Adults (18-64 years)                      | 407 |
| From 65 to 84 years                       | 83  |
| 85 years and over                         | 0   |

## Subject disposition

### Recruitment

Recruitment details:

All subjects approached for the study were either ongoing or new patients referred to the clinics with the diagnosis Psoriasis Vulgaris.

### Pre-assignment

Screening details:

Prior to randomization, the subject entered a washout period (if required) where anti-psoriatic treatment and other relevant medication/treatments were discontinued as defined by the exclusion criteria. The washout/screening period could last for up to 30 days, depending on which disallowed treatments the subject received.

### Period 1

|                              |  |
|------------------------------|--|
| Period 1 title               | Treatment period (overall period)        |
| Is this the baseline period? | Yes                                      |
| Allocation method            | Randomised - controlled                  |
| Blinding used                | Double blind                             |
| Roles blinded                | Subject, Investigator, Monitor, Assessor |

Blinding implementation details:

Due to difference in formulation and packaging, the investigator and staff could not see the IP. Several precautions were taken to maintain the blind. To keep the staff blinded, packing and labelling of the outer box was identical for all IPs, but the content varied. Handling of individual IPs was therefore handled by a designated third unblinded person. This person was only involved in the handling of IP and did not perform any trial related assessment.

### Arms

|                              |              |
|------------------------------|--------------|
| Are arms mutually exclusive? | Yes          |
| <b>Arm title</b>             | MC2-01 Cream |

Arm description:

MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream.

One application daily for 8 weeks.

|  |              |
|--|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | MC2-01 Cream |
| Investigational medicinal product code |              |
| Other name                             |              |
| Pharmaceutical forms                   | Cream        |
| Routes of administration               | Topical use  |

Dosage and administration details:

MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream

|                  |                   |
|------------------|-------------------|
| <b>Arm title</b> | Active Comparator |
|------------------|-------------------|

Arm description:

Calcipotriene/betamethasone (Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks.

|          |                   |
|----------|-------------------|
| Arm type | Active comparator |
|----------|-------------------|

|  |                     |
|--|---------------------|
| Investigational medicinal product name   | Devobet/Devobet gel |
| Investigational medicinal product code   |                     |
| Other name   |                     |
| Pharmaceutical forms   | Gel                 |
| Routes of administration   | Topical use         |
| Dosage and administration details:   |                     |
| Devobet / Devobet gel: (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) |                     |
| <b>Arm title</b>   | Vehicle             |

Arm description:

Vehicle

One application daily for 8 weeks.

|  |             |
|--|-------------|
| Arm type                               | Placebo     |
| Investigational medicinal product name | Vehicle     |
| Investigational medicinal product code |             |
| Other name                             |             |
| Pharmaceutical forms                   | Cream       |
| Routes of administration               | Topical use |

Dosage and administration details:

One application daily for 8 weeks.

| <b>Number of subjects in period 1</b> | MC2-01 Cream | Active Comparator | Vehicle |
|---------------------------------------|--------------|-------------------|---------|
| Started                               | 213          | 209               | 68      |
| Completed                             | 205          | 203               | 55      |
| Not completed                         | 8            | 6                 | 13      |
| Consent withdrawn by subject          | 2            | 3                 | 9       |
| Adverse event, non-fatal              | 1            | 2                 | 2       |
| Withdrew consent, did not make any IP | -            | -                 | 1       |
| Lost to follow-up                     | 5            | 1                 | 1       |

## Baseline characteristics

### Reporting groups

|                       |              |
|-----------------------|--------------|
| Reporting group title | MC2-01 Cream |
|-----------------------|--------------|

Reporting group description:

MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream.

One application daily for 8 weeks.

|                       |                   |
|-----------------------|-------------------|
| Reporting group title | Active Comparator |
|-----------------------|-------------------|

Reporting group description:

Calcipotriene/betamethasone (Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream.  
One application daily for 8 weeks.

|                       |         |
|-----------------------|---------|
| Reporting group title | Vehicle |
|-----------------------|---------|

Reporting group description:

Vehicle

One application daily for 8 weeks.

| Reporting group values                                | MC2-01 Cream | Active Comparator | Vehicle |
|---|--------------|-------------------|---------|
| Number of subjects                                    | 213          | 209               | 68      |
| Age categorical<br>Units: Subjects                    |              |                   |         |
| In utero  |              |                   |         |
| Preterm newborn infants<br>(gestational age < 37 wks) |              |                   |         |
| Newborns (0-27 days)                                  |              |                   |         |
| Infants and toddlers (28 days-23<br>months)           |              |                   |         |
| Children (2-11 years)                                 |              |                   |         |
| Adolescents (12-17 years)                             |              |                   |         |
| Adults (18-64 years)                                  |              |                   |         |
| From 65-84 years                                      |              |                   |         |
| 85 years and over                                     |              |                   |         |
| Age continuous<br>Units: years                        |              |                   |         |
| arithmetic mean                                       | 48.6         | 51.5              | 50.8    |
| standard deviation                                    | ± 13.7       | ± 14.8            | ± 13.1  |
| Gender categorical<br>Units: Subjects                 |              |                   |         |
| Female  | 77           | 96                | 22      |
| Male  | 136          | 113               | 46      |
| Fitzpatrick Skin Type<br>Units: Subjects              |              |                   |         |
| Skintype I  | 6            | 2                 | 0       |
| Skintype II   | 104          | 103               | 29      |
| Skintype III  | 77           | 76                | 25      |
| Skintype IV   | 20           | 19                | 9       |
| Skintype V  | 6            | 7                 | 5       |
| Skintype VI   | 0            | 2                 | 0       |

|   |       |  |  |
|---|-------|--|--|
| <b>Reporting group values</b>                         | Total |  |  |
| Number of subjects                                    | 490   |  |  |
| Age categorical                                       |       |  |  |
| Units: Subjects                                       |       |  |  |
| In utero  | 0     |  |  |
| Preterm newborn infants<br>(gestational age < 37 wks) | 0     |  |  |
| Newborns (0-27 days)                                  | 0     |  |  |
| Infants and toddlers (28 days-23<br>months)           | 0     |  |  |
| Children (2-11 years)                                 | 0     |  |  |
| Adolescents (12-17 years)                             | 0     |  |  |
| Adults (18-64 years)                                  | 0     |  |  |
| From 65-84 years                                      | 0     |  |  |
| 85 years and over                                     | 0     |  |  |
| Age continuous  |       |  |  |
| Units: years  |       |  |  |
| arithmetic mean                                       |       |  |  |
| standard deviation                                    | -     |  |  |
| Gender categorical                                    |       |  |  |
| Units: Subjects                                       |       |  |  |
| Female  | 195   |  |  |
| Male  | 295   |  |  |
| Fitzpatrick Skin Type                                 |       |  |  |
| Units: Subjects                                       |       |  |  |
| Skintype I  | 8     |  |  |
| Skintype II   | 236   |  |  |
| Skintype III  | 178   |  |  |
| Skintype IV   | 48    |  |  |
| Skintype V  | 18    |  |  |
| Skintype VI   | 2     |  |  |

## End points

### End points reporting groups

|                       |              |
|-----------------------|--------------|
| Reporting group title | MC2-01 Cream |
|-----------------------|--------------|

Reporting group description:

MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream.

One application daily for 8 weeks.

|                       |                   |
|-----------------------|-------------------|
| Reporting group title | Active Comparator |
|-----------------------|-------------------|

Reporting group description:

Calcipotriene/betamethasone (Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream.  
One application daily for 8 weeks.

|                       |         |
|-----------------------|---------|
| Reporting group title | Vehicle |
|-----------------------|---------|

Reporting group description:

Vehicle

One application daily for 8 weeks.

### Primary: mPASI

|                 |       |
|-----------------|-------|
| End point title | mPASI |
|-----------------|-------|

End point description:

Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score.

The extent and severity of the participant's psoriasis is assessed using a modified PASI scoring system (minus scalp, face, and flexures) at each 3 areas (arms, trunk and legs) using a scale from 0 - 6, where 0 = no psoriasis involvement and 6 = 90-100% involvement.

The severity is assessed at the 3 areas for each of the sign redness, thickness and scaliness using a scale from 0 - 4, where 0 represents none and 4 represents very severe.

The mPASI score is calculated from the individual scores by use of the following equation:

Arms 0.2 (Redness + Thickness + Scaliness) E = X Trunk 0.3 (Redness + Thickness + Scaliness) E = Y  
Legs 0.4 (Redness + Thickness + Scaliness) E = Z The sum of X + Y + Z = m-PASI score resulting in a minimum score of 0 and a maximum score (worst possible) of 64.8.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

The percent change in mPASI score is defined as the Baseline minus the Week 8 divided by Baseline score multiplied by 100 (this value is negative)

| End point values                        | MC2-01 Cream    | Active Comparator | Vehicle         |  |
|---|-----------------|-------------------|-----------------|--|
| Subject group type                      | Reporting group | Reporting group   | Reporting group |  |
| Number of subjects analysed             | 213             | 209               | 68              |  |
| Units: Percentage Change in mPASI Score |                 |                   |                 |  |
| arithmetic mean (standard deviation)    | -67.5 (± 20.8)  | -63.5 (± 22.2)    | -11.7 (± 21.9)  |  |



## Statistical analyses

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | mPASI                                      |
| Comparison groups                       | Active Comparator v MC2-01 Cream v Vehicle |
| Number of subjects included in analysis | 490  |
| Analysis specification                  | Pre-specified                              |
| Analysis type                           | superiority                                |
| P-value                                 | < 0.05                                     |
| Method                                  | ANCOVA                                     |
| Confidence interval                     |  |
| level                                   | 95 %                                       |
| sides                                   | 2-sided                                    |

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

AEs were collected/assessed from the time of the signature of the informed consent form by the subject and until the final follow-up visit.

Adverse event reporting additional description:

AEs that were considered related to the trial product would be followed until they were resolved, or until the medical condition was stable.

|                 |                |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |    |
|--------------------|----|
| Dictionary version | 22 |
|--------------------|----|

### Reporting groups

|                       |              |
|-----------------------|--------------|
| Reporting group title | MC2-01 Cream |
|-----------------------|--------------|

Reporting group description: -

|                       |                     |
|-----------------------|---------------------|
| Reporting group title | Cal/BDP Combination |
|-----------------------|---------------------|

Reporting group description: -

|                       |         |
|-----------------------|---------|
| Reporting group title | Vehicle |
|-----------------------|---------|

Reporting group description: -

| <b>Serious adverse events</b>                                       | MC2-01 Cream    | Cal/BDP Combination | Vehicle        |
|---|-----------------|---------------------|----------------|
| Total subjects affected by serious adverse events                   |                 |                     |                |
| subjects affected / exposed   | 1 / 213 (0.47%) | 3 / 209 (1.44%)     | 1 / 68 (1.47%) |
| number of deaths (all causes)                                       | 0               | 0                   | 0              |
| number of deaths resulting from adverse events                      | 0               | 0                   | 0              |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                 |                     |                |
| Testicular seminoma (pure)  |                 |                     |                |
| subjects affected / exposed   | 1 / 213 (0.47%) | 0 / 209 (0.00%)     | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 1           | 0 / 0               | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0               | 0 / 0          |
| Gastrointestinal disorders  |                 |                     |                |
| Cholecystitis acute   |                 |                     |                |
| subjects affected / exposed   | 0 / 213 (0.00%) | 0 / 209 (0.00%)     | 1 / 68 (1.47%) |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 0               | 0 / 1          |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0               | 0 / 0          |
| Musculoskeletal and connective tissue disorders                     |                 |                     |                |
| Humerus fracture  |                 |                     |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 213 (0.00%) | 1 / 209 (0.48%) | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Infections and infestations                     |                 |                 |                |
| Herpes zoster meningitis                        |                 |                 |                |
| subjects affected / exposed                     | 0 / 213 (0.00%) | 1 / 209 (0.48%) | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pulmonary tuberculosis                          |                 |                 |                |
| subjects affected / exposed                     | 0 / 213 (0.00%) | 1 / 209 (0.48%) | 0 / 68 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | MC2-01 Cream     | Cal/BDP Combination | Vehicle        |
|---|------------------|---------------------|----------------|
| Total subjects affected by non-serious adverse events |                  |                     |                |
| subjects affected / exposed                           | 10 / 213 (4.69%) | 11 / 209 (5.26%)    | 1 / 68 (1.47%) |
| Infections and infestations                           |                  |                     |                |
| Nasopharyngitis                                       |                  |                     |                |
| subjects affected / exposed                           | 10 / 213 (4.69%) | 11 / 209 (5.26%)    | 1 / 68 (1.47%) |
| occurrences (all)                                     | 10               | 11                  | 1              |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported